FDA Assigns Review Date for Mirdametinib in Genetic Nerve Condition

Retrieved on: 2024-08-29 00:44:24

Tags for this article:

Click the tags to see associated articles and topics

FDA Assigns Review Date for Mirdametinib in Genetic Nerve Condition. View article details on hiswai:

Excerpt

If approved, mirdametinib would be the first therapy for the treatment of adult patients. Neurofibromatosis type 1 is a rare genetic condition ...

Article found on: www.managedhealthcareexecutive.com